Price
Target price
€23.05
€23.05
-3.380%
-0.81
-3.380%
€60.53
19.07.24 / Tradegate
WKN: A2AG6H / Symbol: NTLA / Name: Intellia / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Intellia Therapeutics Inc Stock
Intellia Therapeutics Inc took a tumble today and lost -€0.810 (-3.380%).
We see a rather positive sentiment for Intellia Therapeutics Inc with 17 Buy predictions and 1 Sell predictions.
Based on the current price of 23.05 € the target price of 60 € shows a potential of 160.3% for Intellia Therapeutics Inc which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Intellia Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Intellia Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | -3.380% | -2.537% | 1.766% | -40.852% | -20.380% | -82.208% | 51.745% |
| VBI Vaccines Inc. | -9.260% | -15.417% | 10.741% | -54.697% | 12.830% | -99.216% | -96.989% |
| Organovo Holdings Inc. | -3.840% | -11.470% | -27.417% | -67.991% | -46.589% | -91.923% | -93.858% |
| Matinas BioPharma Holdings Inc | 4.760% | 5.502% | 11.344% | -47.816% | -19.951% | -75.750% | - |
Comments
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $120.00 price target on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
News
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger
Intellia Therapeutics (NASDAQ: NTLA) just published some new data that suggests the company has what it takes to continue being a leader in the gene editing space. While there's still a lot of work
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
Cathie Wood is known for two things: picking out innovators that will go on to score a win over the long run, and getting in on these stocks at a great price. The founder and chief executive officer
These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now
On June 2, Intellia Therapeutics' (NASDAQ: NTLA) CEO John Leonard remarked on the biotech's progress with one of its early-stage clinical programs called NTLA-2002, uttering two very important words